WeSearch

OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence

·6 min read · 0 reactions · 0 comments · 9 views
#purdue pharma#oxycontin#opioid crisis#sackler family#legal settlement
OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence
⚡ TL;DR · AI summary

Purdue Pharma is set to dissolve after a federal judge approved its criminal sentence, clearing the way for a settlement to take effect. The company admitted to misleading regulators and paying doctors to boost opioid prescriptions, contributing to the U.S. overdose epidemic. While the settlement includes up to $7 billion from the Sackler family and the creation of a new public health-focused company, no individuals face criminal charges. Victims expressed frustration that the resolution falls short of justice, with many unlikely to receive compensation.

Key facts
Original article
The Washington Times
Read full at The Washington Times →
Opening excerpt (first ~120 words) tap to expand

NEWARK, N.J. — OxyContin maker Purdue Pharma is set to be dissolved and replaced by a company focused on the public good by the week’s end, as a massive legal settlement resolving thousands of lawsuits takes effect. A federal judge on Tuesday delivered a criminal sentence to the company to resolve a U.S. Department of Justice probe - a last necessary step to clear the way for the settlement. U.S. District Judge Madeline Cox Arleo made her decision after listening to hours of impact statements from people who lost loved ones or struggled with addiction themselves and requested she reject the negotiated sentence. While she didn’t go that far, she said she sympathized with people who bore the brunt of an epidemic linked to more than 900,000 deaths in the U.S. since 1999.

Excerpt limited to ~120 words for fair-use compliance. The full article is at The Washington Times.

Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from The Washington Times